title: Tissue distribution and histopathological effects of titanium dioxide nanoparticles after intravenous or subcutaneous injection in mice.
abstract: Nanoparticles can be formed following degradation of medical devices such as orthopedic implants. To evaluate the safety of titanium alloy orthopedic materials, data are needed on the long-term distribution and tissue effects of injected titanium nanoparticles in experimental animals. In this study, we evaluated the tissue distribution and histopathological effects of titanium dioxide (TiO(2)) nanoparticles (approximately 120 nm diameter) in mice after intravenous (i.v.; 56 or 560 mg kg(-1) per mouse) or subcutaneous (s.c.; 560 or 5600 mg kg(-1) per mouse) injection on two consecutive days. Animals were examined 1 and 3 days, and 2, 4, 12 and 26 weeks after the final injection. When examined by light microscopy, particle agglomerates identified as TiO(2) were observed mainly in the major filtration organs - liver, lung and spleen - following i.v. injection. Particles were still observed 26 weeks after injection, indicating that tissue clearance is limited. In addition, redistribution within the histological micro-compartments of organs, especially in the spleen, was noted. Following s.c. injection, the largest particle agglomerates were found mainly in the draining inguinal lymph node, and to a lesser extent, the liver, spleen and lung. With the exception of a foreign body response at the site of s.c. injection and the appearance of an increased number of macrophages in the lung and liver, there was no histopathological evidence of tissue damage observed in any tissue at any time point.
authors.affiliation: Center for Devices and Radiological Health, Office of Science and Engineering Laboratories, US Food and Drug Administration, Silver Spring, MD 20903, USA. thomas.umbreit@fda.hhs.gov
authors.forename: T H
authors.initials: TH
authors.lastname: Umbreit
authors.forename: S
authors.initials: S
authors.lastname: Francke-Carroll
authors.forename: J L
authors.initials: JL
authors.lastname: Weaver
authors.forename: T J
authors.initials: TJ
authors.lastname: Miller
authors.forename: P L
authors.initials: PL
authors.lastname: Goering
authors.forename: N
authors.initials: N
authors.lastname: Sadrieh
authors.forename: M E
authors.initials: ME
authors.lastname: Stratmeyer
mesh_terms: D000818:Animals; D005260:Female; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008099:Liver / Q000378:metabolism* / Q000473:pathology; D008168:Lung / Q000378:metabolism* / Q000473:pathology; D008198:Lymph Nodes / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000008:administration & dosage / Q000633:toxicity; D013154:Spleen / Q000378:metabolism / Q000473:pathology; D013997:Time Factors; D014018:Tissue Distribution; D014025:Titanium / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity
chemical_list: C009495:titanium dioxide; D014025:Titanium